Rise and shine, everyone, another busy day is on the way. We can tell because countless birds are chirping outside our window, the pace of motor vehicles passing by is picking up, and the official mascots are busy foraging for snacks on the official grounds. As for us, we are engaged in the usual ritual of brewing cups of stimulation. Our choice today is orange cream. As always, you are invited to join us. Meanwhile, here is the latest menu of tidbits for you to digest as you embark on your journey, which we hope is satisfying and rewarding. On that note, time to get cracking. Best of luck, and do keep in touch. …
The U.S. Senate Committee on Health, Education, Labor and Pensions is investigating the prices Novo Nordisk charges for its blockbuster medications, Ozempic and Wegovy, which are highly effective at treating diabetes and obesity but carry steep price tags, The New York Times writes. Sen. Bernie Sanders (I-Vt.), who chairs the committee, maintained the prices must “be lowered in order for consumers to get it, and for governments not to go bankrupt providing it.” The list price of Ozempic, which is authorized for ttype 2 diabetes, is around $968 per package. Wegovy, which is approved for weight loss and to reduce heart risks in some adults with obesity, costs $1,349.02 per package.
The U.S. Department of Justice is conducting a criminal investigation into the McKinsey consulting firm over its past role in advising some of the nation’s largest opioid manufacturers on how to boost sales, The Wall Street Journal reports. Federal prosecutors are also probing whether McKinsey or any of its employees may have obstructed justice in relation to records of its consulting services for opioid producers. A grand jury has been empaneled in Virginia as part of the federal investigation into McKinsey’s opioid-related consulting, some of the people said. The U.S. attorney’s offices in the Western District of Virginia and the District of Massachusetts are jointly conducting the investigation.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect